Matrix metalloproteinase-9 (MMP-9) is a member of the MMP family that has been associated with degradation of the extracellular matrix in normal and pathological conditions. A unique characteristic of MMP-9 is its ability to exist in a monomeric and a disulfide-bonded dimeric form. However, there exists a paucity of information on the properties of the latent (pro-MMP-9) and active MMP-9 dimer. Here we report the purification to homogeneity of the monomer and dimer forms of pro-MMP-9 and the characterization of their biochemical properties and interactions with tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Gel filtration and surface plasmon resonance analyses demonstrated that the pro-MMP-9 monomeric and dimeric forms bind TIMP-1 with similar affinities. In contrast, TIMP-2 binds only to the active forms. After activation, the two enzyme forms exhibited equal catalytic competence in the turnover of a synthetic peptide substrate with comparable kinetic parameters for the onset of inhibition with TIMPs and for dissociation of the inhibited complexes. Kinetic analyses of the activation of monomeric and dimeric pro-MMP-9 by stromelysin 1 revealed K m values in the nanomolar range and relative low k cat values (1.9 ؋ 10 ؊3 and 4.1 ؋ 10 ؊4 s
1 also known as gelatinase B, is a member of the MMP family of zinc-dependent endopeptidases known for their ability to degrade many extracellular matrix (ECM) components (1, 2) . MMP-9 is secreted in a latent form (pro-MMP-9) by a variety of normal and transformed cells and has been implicated in the pathogenesis of several human diseases including arthritis (3), cardiovascular disease (4, 5) , and cancer metastasis (6, 7) . MMP-9 has also been suggested to play a role in the degradation of ECM during inflammation (8) , wound healing (9, 10) , trophoblast implantation (11) , and angiogenesis (12) . Structurally, pro-MMP-9 is closely related to pro-MMP-2 (gelatinase A) with both enzymes containing a fibronectin-like type II module (gelatin-binding domain) inserted into the catalytic domain that is thought to facilitate interaction of the enzymes with collagen molecules (13, 14) . The zymogenic forms of both enzymes interact, via their C-terminal domain (hemopexin-like domain), with tissue inhibitors of metalloproteinases (TIMPs), a family of specific endogenous MMP inhibitors (15, 16) . Pro-MMP-9 binds to TIMP-1 (1), whereas pro-MMP-2 binds to TIMP-2 (17) and to TIMP-4 (18) . After activation, any TIMP molecule efficiently inhibits the enzymatic activity by binding to the catalytic domain of the MMP (16) .
Despite the similarities that exist between pro-MMP-9 and pro-MMP-2, the former is unique in several aspects including its gene regulation, structure, and function (2, 14) . Pro-MMP-9 is glycosylated and contains an additional 54-amino acid proline-rich insertion of unknown function between the catalytic and the hemopexin-like domains (1) . In addition, pro-MMP-9, in contrast to pro-MMP-2, exists in two major forms: a monomeric (ϳ92 kDa) and a disulfide-bonded homodimeric (ϳ220 kDa) form (1) . Both the monomeric and dimeric forms of pro-MMP-9 forms have been identified in a variety of pro-MMP-9-producing cells including normal (19 -21) and tumor cells (1, 22) and in various biological fluids (23, 24) and tissues (25, 26) , indicating that they are physiological forms of the enzyme. In addition, a 125-130-kDa form of pro-MMP-9 present in neutrophil granules has been reported to be a complex of the enzyme with lipocalin (NGAL) (19, 20) .
Studies examining the activation, catalytic activity, and interactions with TIMPs of pro-MMP-9 and MMP-9 have focused mainly on the monomeric form of the enzyme. Thus, little is known about the biochemical properties of the homodimeric form. A previous study examined the structural requirements for the formation of the pro-MMP-9 homodimer and its interaction with TIMP-1 (27) . However, the kinetics of activation, the catalytic efficiencies, and the inhibition by TIMPs of the monomeric and dimeric forms remained unknown. Here, we report the first comprehensive study aimed at characterizing the biochemical properties of both the latent and active pure monomeric and dimeric forms.
EXPERIMENTAL PROCEDURES
Buffers-Buffer C (50 mM HEPES (pH 7.5), 150 mM NaCl, 5 mM CaCl 2 , and 0.02% Brij-35); buffer B (10 mM sodium acetate (pH 4.5)); buffer W (7.8 mM NaH 2 PO 4 , 8 mM Na 2 HPO 4 (pH 7.2), 137 mM NaCl, 0.1 mM CaCl 2 , 3 mM KCl, 1.5 mM KH 2 PO 4 , and 0.02% Tween 20); buffer R (50 mM HEPES (pH 7.5), 150 mM NaCl, 5 mM CaCl 2 , 0.01% Brij-35, and 1% (v/v) Me 2 SO); buffer D (50 mM Tris (pH 7.4), 150 mM NaCl, 5 mM CaCl 2 , and 0.02% Brij-35) and lysis buffer (25 mM Tris-HCl (pH 7.5), 1% Nonidet P-40, 100 mM NaCl, 5 mM EDTA, 20 mM N-ethylmaleimide, 10 g/ml aprotinin, 1 g/ml pepstatin A, 1 g/ml leupeptin, 2 mM benzamidine, and 1 mM phenylmethylsulfonyl fluoride).
Expression and Purification of Pro-MMP-9 and TIMPs-Human recombinant pro-MMP-9, TIMP-1, and TIMP-2 were produced in mammalian cells using a recombinant vaccinia virus mammalian cell expression system, as described previously (28) . Pro-MMP-9 was purified to homogeneity from the media of infected HeLa cells by gelatin-agarose chromatography, as described previously (29) . The concentration of pro-MMP-9 was determined using the molar extinction coefficient of 114,360 M Ϫ1 cm Ϫ1 (14) . Recombinant TIMP-1 and TIMP-2 were purified as described previously (30) . Protein concentrations of TIMP-1 and TIMP-2 were determined using their molar extinction coefficients of 26,500 and 39,600 M Ϫ1 cm
Ϫ1
, respectively (16) .
Purification of the Monomeric and Dimeric Forms of Pro-MMP-9 -A
sample (7600 pmol) of purified pro-MMP-9 diluted in buffer C was layered onto four polyallomer tubes containing a preformed 20 -35% glycerol gradient prepared in buffer C. The tubes were then centrifuged (63 h, 4°C) in a SW41 rotor at 37,000 rpm, after which nine fractions (ϳ200 l each) were collected and assayed for the presence of monomeric or dimeric forms by gelatin-zymography. Fractions containing homogeneous monomeric (pro-MMP-9 M ) or dimeric (pro-MMP-9 D ) forms were pooled, and their protein concentrations were determined from the molar extinction coefficients: for pro-MMP-9 M , 103,645 M Ϫ1 cm
Ϫ1
; and for pro-MMP-9 D , 198,609 M Ϫ1 cm Ϫ1 (31) . Radioiodination of TIMPs-TIMP-1 and TIMP-2 were iodinated with carrier free Na 125 I (100 mCi/ml, Amersham Pharmacia Biotech) using IODOGEN (Pierce) as described previously (30) . The specific activities of 125 I-TIMP-1 and 125 I-TIMP-2 were calculated to be 0.035 and 0.045 Ci/pmol, respectively.
Size-exclusion Chromatography-Ten pmol of purified pro-MMP-9 M or pro-MMP-9 D were each incubated (1 h, 22°C) with either I-TIMP-2 bound to the pro-MMP-9 forms was determined from the specific activity.
SDS-PAGE and Gelatin Zymography-SDS-PAGE was performed according to Laemmli (32) . Proteins were visualized by staining overnight with a 0.25% solution of Coomassie Brilliant Blue R-250 in 45% methanol and 10% acetic acid, and destained in a solution of 20% methanol and 10% acetic acid. Gelatin zymography was performed as described (33) .
Preparation of Breast Tumor Extract-A fresh tissue biopsy (ϳ50 mg) (kindly provided by Dr. D. Visscher, Department of Pathology, Harper Hospital, Detroit, MI) of a breast carcinoma was minced into small pieces and resuspended in 500 l of cold lysis buffer. The pieces were homogenized on ice with a pestle (Kontes, Vineland, NJ) in a microcentrifuge tube, followed by a centrifugation (14,000 rpm) of the homogenate for 10 min at 4°C. The supernatant was collected, and the protein concentration was determined by the BCA protein assay (Pierce). The protein concentration was adjusted to 1 g/l of 1ϫ sample buffer, and the sample was then subjected to gelatin zymography as described above and to immunoblot analysis, as described (21) , using an anti-MMP-9 rabbit polyclonal antibody (pAb 109) raised against a synthetic peptide (APRQRQSTLVLTPGDLRT) from the prodomain of human pro-MMP-9 (a generous gift from Dr. Stetler-Stevenson, NCI, National Institutes of Health, Bethesda, MD).
Pulse-Chase Analysis of Pro-MMP-9 Biosynthesis-Monkey kidney BS-C-1 cells (80% confluent) in 60-mm dishes were co-infected with 3 plaque-forming units/cell of vTF7-3 vaccinia virus encoding for T7 RNA polymerase and with 3 plaque-forming units/cell of a recombinant vaccinia virus containing the full-length cDNA of human pro-MMP-9 (vT7-GELB) as described (28) . Four hours after infection, the medium was aspirated and the cell monolayer was gently washed with warm PBS.
The cells were incubated (30 min) with 1.5 ml/dish starving medium (Dulbecco's modified Eagle's medium without methionine supplemented with 25 mM Hepes and 0.5% fetal bovine serum). The cells were then pulsed with 500 Ci/ml [ 35 S]methionine in starvation medium (1.5 ml/dish) for 15 min at 37°C. After the pulse, the dishes were placed on ice, the medium was aspirated and the cells were washed twice with PBS before the addition of 1 ml/dish chase medium (Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 4.8 mM methionine). At the end of the chase periods (0 -240 min at 37°C), the medium was collected; the cells were washed with cold PBS and lysed with 1 ml/dish lysis buffer. The lysates were clarified by a brief centrifugation and were pre-absorbed on protein G-Sepharose beads. The lysates and the media were subjected to immunoprecipitation with either a mAb to pro-MMP-9 (CA-209) or mouse IgG and protein G-Sepharose beads, as described (21) . The immunoprecipitates were mixed with Laemmli sample buffer, with or without ␤-mercaptoethanol, and resolved by 8 -16% SDS-PAGE followed by autoradiography.
Fluorometric Activity Assay for MMP-9 M and MMP-9 D -To obtain the active monomer and dimer, purified pro-MMP-9 M (100 pmol) or pro-MMP-9 D (60 pmol) in buffer C were incubated (2 h at 37°C) with 25 pmol of heat-activated recombinant human stromelysin 1 (MMP-3, a generous gift from Dr. Paul Cannon, Center for Bone and Joint Research, Palo Alto, CA). The activated monomer (MMP-9 M ) and dimer (MMP-9 D ) were then subjected to gelatin-agarose chromatography to remove stromelysin 1, as described (30 , respectively, as determined by the method of Gill and von Hippel (31) . The activities of the purified MMP-9 M and MMP-9 D were assayed using the fluorescence quenched substrate MOCAcPLGLA 2 pr(Dnp)-AR-NH 2 (Peptide Institute, Inc. Japan), as described (30, 34) . Each assay was carried out at 25°C in 2 ml (final volume) of buffer R containing enzyme and and/or inhibitor at the indicated concentrations. The substrate concentration was varied from 0.05 to 8.0 M. The enzyme concentrations were 0.2 and 0.1 nM for MMP-9 M and MMP-9 D , respectively. Substrate hydrolysis was monitored using a Photon Technology International (PTI) fluorescence spectrophotometer with excitation and emission wavelengths set at 328 and 393 nm, respectively, controlled by a Pentium™ computer using the RatioMaster™ hardware and FeliX™ software provided by PTI. The excitation and emission band passes were 1 and 3 nm, respectively. Fluorescent measurements were taken with a 4-s integration time. Three initial rate determinations were made for each substrate concentration. The K m and V max values were determined by non-linear regression analyses using GraphPad Prism™ and examined by double-reciprocal analysis by linear regression using LINEST (Microsoft Excel™ version 5.0).
Degradation of Gelatin by MMP-9 M and MMP-9 D -Increasing concentrations (0.07-0.3 nM) of active site-titrated (with TIMP-1) MMP-9 M and MMP-9 D were incubated with 1 M fluorescein-labeled DQ™ gelatin (Molecular Probes, Eugene, OR) in buffer D, in a total volume of 2 ml. Substrate hydrolysis was monitored over a 1-h period at 25°C using a PTI spectrofluorometer at excitation and emission wavelengths of 495 and 515 nm, respectively. Excitation and emission band passes were 1 and 3 nm, respectively. Background fluorescence due to DQ™ gelatin was measured with substrate in the absence of enzymes and was subtracted from each trace. A fluorescein (Molecular Probes) standard curve was used to correlate the fluorescence increase with the amount of released fluorescein.
Kinetic Analysis of the Activation of Pro-MMP-9 M and Pro-MMP-9 D by Stromelysin 1-Human recombinant pro-stromelysin 1 was heat activated at 55°C for 1 h. The amount of catalytically competent stromelysin 1 was determined by active-site titration with human recombinant TIMP-1. Stromelysin 1 activity was measured with 5 M fluorogenic peptide substrate MOCAcRPKPVE-Nva-WRK(Dnp)-NH 2 (35) (Peptides International, Louisville, KY) in buffer R, at excitation and emission wavelengths of 325 and 393 nm, respectively. Activation of pro-MMP-9 M or pro-MMP-9 D was monitored in reaction mixtures containing 2-120 nM of either substrate and 0.5 nM stromelysin 1 in 70 l of buffer D at 37°C. At varying times, aliquots (20 l) of the reaction mixture were added to acrylic cuvettes containing 2 ml of 7 M MOCAcPLGLA 2 pr(Dnp)-AR-NH 2 in buffer R at 25°C. Less than 10% of hydrolysis of the fluorogenic substrate was monitored, as described by Knight (36) . Hydrolysis of this peptide by stromelysin 1 at the concentrations used (0.5-9 nM) was insignificant when compared with the hydrolysis by MMP-9. The MMP-9 (monomer or dimer) concentrations were calculated using the Michaelis-Menten equation and the k cat and K m values for the reaction of the enzyme (monomer and dimer) with the fluorogenic substrate, as described above. Initial velocities of pro-MMP-9 M or pro-MMP-9 D activation were determined from the linear increase in MMP-9 concentration as a function of time. The kinetic parameters k cat and K m were obtained by non-linear least squares fitting of the initial rate dependence on the total pro-MMP-9 concentration to the Michaelis-Menten equation using SCIENTIST (MicroMath Scientific Software, Salt Lake City, UT). The values for t 1/2 were calculated from the following general relationship for first-order reactions:
Determination of Kinetic and Equilibrium Constants by SPR-Interactions of latent and active monomer and dimer pro-MMP-9/MMP-9 with TIMP-1 and TIMP-2 were studied using a Fison Iasys instrument. TIMP-1 (69 pmol) and TIMP-2 (42 pmol) were immobilized onto activated CM5 sensor cells (Fison), as described (30) . Under these conditions, 320 -380 arc s of TIMP-2 and 310 -360 arc s of TIMP-1 were covalently coupled. Binding reactions were carried out essentially as described previously (30) . The equilibrium constants (K d ) were calculated from the rate constants for association (k a ) and dissociation (k d ) from the equation (2) for the low and high affinity binding sites, respectively. The binding constants for each analyte protein were determined in duplicate using at least six different concentrations of analyte (2-400 nM), in a final volume of 200 l, where the response increased as a function of analyte concentration. For TIMP-1 and TIMP-2, pro-MMP-9 M and active MMP-9 M were titrated from 10 to 125 nM and proMMP-9 D and active MMP-9 D were titrated from 5 to 75 nM. Furthermore, each analyte protein (100 nM) was subjected to analysis using a derivatized sensor cell to determine the amount of nonspecific binding to the carboxymethyl dextran matrix. No binding of the analyte protein to the underivatized matrix was observed. The binding curves were analyzed using the nonlinear data-fitting program Iasys Fastfit™, using both monophasic and biphasic models to obtain the rate constants. Analysis of the data fit the biphasic model, as we have previously described in detail (30) .
Enzyme Inhibition Studies-To determine the inhibition constant (K i ) of TIMP-1 and TIMP-2 for the active monomer and dimer, the rate constants (k on and k off ) were determined under the following conditions, and from these the K i was calculated (i.e. k off /k on ). The fluorogenic peptide substrate concentration for each assay was 7 M, a concentration ϳ5-fold greater than the experimentally determined K m for the reaction of the substrate with MMP-9 M and MMP-9 D . TIMP-1 (0 -30 nM) or TIMP-2 (0 -60 nM) were added to the fluorogenic substrate solution, and the assay was initiated by addition of enzyme to give a final concentration of 1 nM for MMP-9 M and 0.5 nM for MMP-9 D . The reaction was allowed to proceed for 6 min, and the rate of substrate cleavage was measured in triplicate for each inhibitor concentration examined. The first-order rate constant, k, was determined from the intersection point of the tangent to the curve at I ϭ x to the curve at I ϭ 0 where k ϭ 1/t, as described (37) , where the data points gave equal increments of product formation as a function of time in the absence of inhibitor. The first-order rate constant, k, for each TIMP concentration was plotted as a function of TIMP concentration. The slope and error of the slope of this line gives the on-rate, k on , as determined by linear regression using LINEST (Microsoft Excel™ version 5.0). The dissociation rate constants (k off ) were determined in triplicate as follows. MMP-9 M or MMP-9 D (300 nM) and inhibitors (330 nM) were incubated for 1 h at 25°C. These reaction mixtures were added to a cuvette containing 2 ml of a 12 M peptide substrate solution. The final enzyme concentration was 0.5 nM. The recovery of enzyme activity was followed for up to 40 min, and the data were analyzed as described (38) . The error of the slope of this line was determined by linear regression using LINEST (Microsoft Excel™ version 5.0). The inhibition constants (K i ) were calculated from K i ϭ k off /k on .
Computer Modeling-The primary sequence of pro-MMP-9 was obtained from the Swiss-Prot data bank (code COG9_HUMAN, total 707 amino acids). A complete model of pro-MMP-9 was constructed as described below. The signal peptide was removed from the complete sequence, and the remaining sequence was divided into prodomain, catalytic, gelatin-binding, and hemopexin-like domains. Homology models were constructed using the COMPOSER module in Sybyl version 6.4; the modeling of the three-dimensional structure of the catalytic domain of MMP-9 has been published previously (13) . The hemopexin-like domain of pro-MMP-9 was modeled using the structures of the hemopexin-like domains of pro-MMP-2 (Protein Data Bank codes 1gen and 1rtg), fibroblast collagenase (code 1fbl), and collagenase-3 (code 1pex), following similar procedures that were used for the modeling of the catalytic domain (13, 39 -41). The gelatin-binding domain was modeled using the NMR structure of the fibronectin type-II model (code 1fn2) (42) . The prodomain of pro-MMP-9 was modeled based on the x-ray structure of homologous prodomain of stromelysin-1 (code 1slm) (43) . In modeling the prodomain, residues upstream of 44 were considered in the homology model building because no homologous sequences were found from residues 21-43. Individual domains of human pro-MMP-9 were thus constructed using homology modeling and three-dimensional structure alignment, and the two contiguous domains were organized and linked appropriately in space. The collagen V-like hinge region of pro-MMP-9 was not modeled due to the lack of any homologous protein that could serve as a three-dimensional template. The complete structure of pro-MMP-9 was energy-minimized using AMBER 5.0 software package on a Silicon Graphics Octane workstation with dual processors, for 20,000 cycles (13) . However, we have disclosed in this report only the arrangements of the contiguous regions of the prodomain and catalytic domains, since they are pertinent to the discussion. The graphical analysis of the resulting structure was performed using Sybyl software version 6.4. Fig. 1 , pro-MMP-9 in monomeric (ϳ92 kDa) and dimeric (ϳ210 kDa) forms can be found in preparations of purified recombinant enzyme (Fig. 1, lane 2) , in serum-free conditioned media of tumor necrosis factor-␣-treated non-malignant MCF10A breast epithelial cells (Fig. 1, lane 3) and in a tissue homogenate derived from a human breast carcinoma biopsy (Fig. 1, lane 4) . The tumor sample contains several gelatinolytic bands migrating at ϳ72, 85, 92, 130, and 225 kDa. To confirm the nature of the MMP-9 forms detected in the tumor homogenate, we carried out an immunoblot analysis using a polyclonal antibody to the prodomain of pro-MMP-9. The tumor homogenate contained two immunoreactive forms of ϳ92 and 225 kDa (Fig. 1, lane 5 ) consistent with these forms being the monomeric and dimeric forms of pro-MMP-9.
RESULTS

Expression of Pro-MMP-9 M and Pro-MMP-9 D -As shown in the zymogram of
Biosynthesis of Pro-MMP-9 M and Pro-MMP-9 D -The biosynthesis of pro-MMP-9 M and pro-MMP-9 D was examined by pulse-chase analysis in BSC-1 cells infected with a recombinant vaccinia virus expressing human pro-MMP-9. After the chase period, the resulting media and cell lysates were immunoprecipitated with a mAb against pro-MMP-9 and subjected to SDS-PAGE analysis under non-reducing and reducing conditions followed by autoradiography. As shown in Fig. 2 , the pro-MMP-9 M precursor form (ϳ85 kDa) was rapidly synthesized and gradually converted to the fully glycosylated mature form (ϳ92 kDa), which was then secreted into the extracellular space (Fig. 2, extracellular) . Precursor pro-MMP-9 D (ϳ190 kDa) was clearly noticeable in the lysates as early as 5 min after the pulse, consistent with the dimer being composed of two precursor monomers. Thus, under these conditions, dimerization occurs intracellularly and appears to be independent of glycosylation. After 30 min, a dimer of ϳ210 kDa was detected in the lysates, possibly representing dimerization of mature monomer forms or, alternatively, complete glycosylation of the immature dimer (Fig. 2) . After 60 min into the chase period, the mature pro-MMP-9 monomer and dimer were detected in the media (Fig. 2, extracellular) . In the presence of a reducing agent (Fig. 2, ϩ␤-mercaptoethanol) , only pro-MMP-9 M was detected (21) consistent with dimerization involving the formation of a disulfide bond (27) . Pulse-chase samples prepared in the presence or absence of 20 nM N-ethylmaleimide showed similar results demonstrating that dimerization was not a consequence of in vitro oxidation during cell lysis (data not shown).
A ϳ120-kDa protein of unknown origin was also immunoprecipitated from the media and was only observed under nonreducing conditions (Fig. 2, extracellular) . The 120-kDa protein is not likely to be a complex of the monomeric form with TIMP-1 (31 kDa), as reported by Moll et al. (22) , since it did not co-immunoprecipitate with a polyclonal antibody to TIMP-1 (data not shown), known to co-precipitate the enzyme/inhibitor complex (21) . Consistently, a radiolabeled 31-kDa protein was not detected under reducing conditions in the pulse-chase experiment. Indeed, vaccinia-infected cells do not express endogenous TIMPs (28) . Furthermore, a 25-kDa protein, consistent with the molecular mass of lipocalin (19, 20) , which is known to form a complex with neutrophil pro-MMP-9, could not be detected under reducing conditions (Fig. 2, ϩ␤-mercaptoethanol) . Interestingly, the 120-kDa protein was not detected in purified preparations of recombinant pro-MMP-9 (Fig. 3) , suggesting that it is a minor component.
Purification of Pro-MMP-9 M and Pro-MMP-9 D -To characterize the biochemical properties of the pure monomeric and dimeric forms, these forms were isolated from each other using glycerol-gradient sedimentation. Since pro-MMP-9 D sediments faster than pro-MMP-9 M , near base-line separations were achieved as shown in the zymogram of Fig. 3A . Gradient fractions containing pro-MMP-9 M or pro-MMP-9 D were pooled, activated or not with stromelysin 1, and examined by non-reducing SDS-PAGE followed by Coomassie Blue staining (Fig. 3B) and by gelatin zymography (Fig. 3C) . These analyses revealed that the purified pro-MMP-9 M (Fig. 3, B and C, lane 3) or pro-MMP-9 D (Fig. 3B, lane 5, and C, lane 4) were homogeneous. Incubation of pro-MMP-9 M and pro-MMP-9 D with stromelysin 1 resulted in the processing of these two forms to low molecular mass species of ϳ82 kDa (Fig. 3B, lane 4, and B, lane 5 ) and ϳ200 kDa (Fig. 3, B and C, lane 6) . The ability of MMP-9 M and MMP-9 D to degrade a natural substrate was examined using fluorescein-labeled gelatin. These data showed that MMP-9 M and MMP-9 D cleaved the gelatin substrate with similar catalytic efficiency, as indicated by the identical linear dependence of the initial rates of gelatin cleavage as a function of enzyme concentration (0 -0.3 nM) (data not shown). Determination of the kinetic parameters (k cat and K m ) of this reaction was not possible due to the collisional quenching of the fluorescein-labeled fragments released at the concentrations of gelatin used (25 nM to 1 M).
Catalytic Competence of MMP-9 M and MMP-9 D -We
Differential Kinetics of Activation of Pro-MMP-9 M and Pro-MMP-9 D by Stromelysin 1-Stromelysin 1 is an efficient activator of pro-MMP-9 (44, 45
). Therefore, we wished to compare the kinetics of activation of isolated pro-MMP-9 M and pro-MMP-9 D by stromelysin 1. After exposure of pro-MMP-9 M or pro-MMP-9 D to stromelysin 1, the enzymatic activities of the generated active species were measured using the fluorogenic peptide substrate. Nonlinear least-squares analysis of the data according to the Michaelis-Menten equation provided the kinetic parameters listed in Table I . Thus, pro-MMP-9 D is acti- FIG. 2 . Pulse-chase analysis of pro-MMP-9 biosynthesis. Infected BSC-1 cells were subjected to pulse-chase analysis, as described under "Experimental Procedures." At the end of the chase periods (0 -240 min), the cells (intracellular) and the media (extracellular) were subjected to immunoprecipitation with an anti-MMP-9 mAb (CA-209). The immunoprecipitates were subjected to 8 -16% SDS-PAGE analysis under non-reducing (Ϫ␤-ME) or reducing (ϩ␤-ME) conditions followed by autoradiography.
14 C-Labeled molecular weight standards, electrophoresed under reducing conditions, were used as reference. vated with a catalytic efficiency 10-fold lower than that of pro-MMP-9 M due to a difference in the values of k cat since the K m values are within the experimental error. At subsaturating substrate concentrations, the initial rates of activation of pro-MMP-9 M and pro-MMP-9 D varied linearly with stromelysin 1 concentration and the slopes of the lines correlated with the determined kinetic parameters.
Pro-MMP-9 M and Pro-MMP-9 D Bind TIMP-1-Previous experiments in our laboratory, in which pro-MMP-9 and TIMP-1 were co-expressed in the vaccinia expression system, demonstrated that both the monomeric and dimeric forms of the enzyme co-precipitated with TIMP-1 using either anti-TIMP-1 or anti-MMP-9 antibodies. 2 These studies suggested that both pro-MMP-9 forms bind the inhibitor. Here we investigated the ability of purified pro-MMP-9 M and pro-MMP-9 D to form a stable complex with TIMP-1 using size-exclusion chromatography. Prior to gel filtration, purified pro-MMP-9 M or pro-MMP-9 D was incubated with molar excess concentrations of 125 I-TIMP-1 and the mixtures were then chromatographed on a Superose-12 column. Fig. 4 shows the column profiles of 125 I-TIMP-1 alone and of mixtures of 125 I-TIMP-1 with either pro-MMP-9 M or pro-MMP-9 D . These column profiles (Fig. 4) and analysis of the eluted fractions by immunoblot and autoradiography (data not shown) demonstrated that a fraction of the 125 I-TIMP-1 co-chromatographed with the monomeric and dimeric forms of proMMP-9 consistent with formation of stable complexes. The sum of the radioactivity present in peak 1 (enzyme/inhibitor complex) and in peak 2 ( 125 I-TIMP-1 alone) of the column profiles revealed an enzyme: inhibitor ratio of 1:1.26 for the pro-MMP-9 M /TIMP-1 complex and of 1:1.84 for the pro-MMP-9 D /TIMP-1 complex consistent with a stoichiometry of 1:1 and 1:2, respectively. As controls, mixtures of either pro-MMP-9 M or pro-MMP-9 D with 125 I-TIMP-2 chromatographed under the same conditions failed to demonstrate complex formation (data not shown). These experiments demonstrate that both the monomeric and dimeric forms of pro-MMP-9 bind TIMP-1.
SPR Analyses of Latent and Active Monomer and Dimer with TIMP-1 and TIMP-2-Previously
, we reported the binding affinities of pro-MMP-9 and MMP-9 with TIMP-1 and TIMP-2 using SPR (30). Here we used SPR to examine the binding kinetics of purified pro-MMP-9 M and pro-MMP-9 D and their active species with TIMP-1 and TIMP-2. As expected, pro-MMP-9 M and pro-MMP-9 D did not bind to TIMP-2. However, the active MMP-9 species demonstrated distinct association and dissociation phases of binding to TIMP-2. The calculated association rate constant (k a ), dissociation rate constant (k d ), and equilibrium constant (K d ) values from the SPR analyses are summarized in Table II . These analyses indicated the existence of high and low affinity binding sites, as reported previously for the binding of TIMP-1 to pro-MMP-9 and MMP-9 (30), known to be a mixture of both monomeric and dimeric forms. The data also indicated a somewhat greater affinity (1.4 -1.7-fold) of the dimeric form (latent and active) for TIMP-1 at the high affinity site (Table II) . Both MMP-9 M and MMP-9 D bound to TIMP-2 with biphasic binding kinetics. However, the affinity of TIMP-2, at the high affinity site, for the active MMP-9 forms was ϳ2-fold lower than that exhibited by TIMP-1 (Table II) .
K i Determination of TIMP-1 and TIMP-2 for MMP-9 M and MMP-9 D -
To further examine the binding of TIMP-1 and TIMP-2 to the purified MMP-9 forms, we carried out enzyme inhibition studies. As we have previously reported with MMP-2 and MMP-9 (30), TIMP-1 and TIMP-2 inhibited the active monomeric and dimeric species in a process consistent with slow binding inhibition (data not shown). Table III 
TABLE I
Kinetic parameters for pro-MMP-9 monomer and dimer activation by stromelysin-1 Increasing concentrations of pro-MMP-9 M and pro-MMP-9 D (2-120 nM) were incubated with 0.5 nM stromelysin 1 in a total volume of 70 l of buffer D, at 37°C. MMP-9 M and MMP-9 D were assayed with the fluorogenic substrate (7 M) in buffer R at 25°C. Analogous results were obtained from three independent experiments. The kinetic parameters were evaluated from nonlinear regression analysis, as described under "Experimental Procedures."
Pro-MMP-9 M 13 Ϯ 3 (1.9 Ϯ 0.1) ϫ 10
Ϫ3
( I-TIMP-1, respectively. The mixtures were then subjected to gel filtration using a Superose-12 column, as described under "Experimental Procedures." The radioactivity in the eluted fractions (350 l) was measured in a ␥ counter, and the amount (picomoles) of TIMP-1 was determined from the specific activity.
from the inhibition experiments are in agreement with the values determined by SPR analyses (Table II) . Hence, the calculated K i values of TIMP-1 and TIMP-2 were in the nanomolar range and within 2-5-fold of the K d values determined by SPR.
DISCUSSION
Pro-MMP-9 is unique among the members of the MMP family in that it forms dimers consisting of covalently tethered monomers via a disulfide bond that can also be found in tissues. However, the biochemical properties of the monomeric and dimeric forms remained unknown. We have shown that the process of dimerization occurs intracellularly and concomitantly with glycosylation. Accordingly, both the precursor and mature forms of the pro-MMP-9 D can be detected in the cellular compartment during pro-MMP-9 biosynthesis. However, only mature pro-MMP-9 M and pro-MMP-9 D are secreted. Under reducing conditions, only monomeric pro-MMP-9 was detected, consistent with disulfide-bond formation during intracellular dimerization. The identity of the cysteine residue(s) that predisposes pro-MMP-9 to dimerization is unknown. Based on the crystal structure of the homologue C-terminal domain of pro-MMP-2 (36), the conserved Cys 516 and Cys 704 in the hemopexin-like domain of pro-MMP-9 are likely to be disulfidebonded precluding a role for these cysteine residues in dimer formation. Site directed mutagenesis studies also excluded Cys 674 in this process (27, 46) . Consistently, a computational model of the three-dimensional structure of the hemopexin like-domain of pro-MMP-9, 3 based on the crystal structure of the same domain of pro-MMP-2 (39), suggests that Cys 674 , although unique to pro-MMP-9, is unlikely to be involved in dimerization, since it is solvent-inaccessible. Pro-MMP-9 contains an additional Cys at position 468 located in the collagen V-like hinge region that may be responsible for the dimerization. However, its role in dimer formation remains to be established. Expression of pro-MMP-9 in the vaccinia system allowed us to obtain sufficient amount of recombinant enzyme for isolation and purification of the monomeric species from the dimeric form. Several procedures were tested to purify the monomer from the dimer including gelatin-affinity chromatography (27) , ion-exchange chromatography, gel filtration, and glycerol gradient sedimentation. However, the latter proved to be the most efficient and consistent method to obtain homogeneous preparations of monomer and dimer. Purified pro-MMP-9 M and pro-MMP-9 D were examined for their interactions with TIMP-1 and TIMP-2 using gel filtration and SPR analyses. These studies showed that both pro-MMP-9 species could form stable complexes with TIMP-1 but not with TIMP-2. These data are in disagreement with a previous study showing a lack of complex formation between TIMP-1 and pro-MMP-9 D (27) . This discrepancy may be related to the method of purification of the monomeric from the dimeric form (gelatin-affinity chromatography (Ref. 27 ) versus glycerol-gradient sedimentation) and/or the use of recombinant TIMP-1 expressed in bacteria (27) versus mammalian cell-expressed TIMP-1 (this study). We have found that the binding of TIMP-1 to pro-MMP-9 M or pro-MMP-9 D was consistent with a stoichiometry of 1:1 and 2:1 molar ratio, respectively, suggesting that two high affinity binding sites for TIMP-1 are available in the dimeric form. These sites are likely to be located in the hemopexin-like domain, which is the major TIMP-1 binding site of pro-MMP-9 (44). The gel filtration data were supported by SPR analyses demonstrating binding of TIMP-1 to the monomer and dimer (latent and active) with biphasic kinetics. Thus, dimerization has no apparent effect on the binding kinetics of TIMP-1 and the affinity values are in agreement with our previous data with pro-MMP-9 and MMP-9, monomer and dimer mixtures (30) . Although the nature of the second TIMP-1 binding site is unknown, the results presented here suggest that it is structurally different from the site required for dimerization since the dimer also binds TIMP-1. These results are in agreement with the study of Goldberg et al. (27) showing that mutations disrupting TIMP-1 binding had no effect on dimerization. Consistent with our previous SPR data with pro-MMP-9 (30) and the gel filtration experiments, TIMP-2 showed no binding to pro-MMP-9 M or pro-MMP-9 D . However, both MMP-9 M and MMP-9 D exhibited biphasic TIMP-2 binding kinetics with an affinity that was ϳ2-fold lower than that exhibited by TIMP-1, at the high affinity site. Consistently, enzyme inhibition studies showed that both MMP-9 M and MMP-9 D were equally inhibited by 3 I. Massova, L. Kotra, and S. Mobashery, unpublished data. (2) refer to the first and the second phase of kinetics. monomer and dimer interactions with TIMPs To determine k on MMP-9 M and MMP-9 D were added to a 7 M fluorogenic substrate solution in buffer R containing increasing TIMP-1 (0 -30 nM) or TIMP-2 (0 -60 nM) resulting in final enzyme concentrations of 1 and 0.5 nM, respectively. The dissociation rate constants were determined by diluting a preincubated (for 1 h at 25°C) reaction mixture containing enzymes (300 nM) and inhibitors (330 nM) into 2 ml of a 12 M fluorogenic substrate solution in buffer R, resulting in a final enzyme concentrations of 0.5 nM. All assays were carried out in triplicate. The k on , k off , and K i values were calculated as described under "Experimental Procedures." Kinetic studies with MMP-9 M and MMP-9 D indicate no significant differences in the hydrolytic capacity of the MMP-9 forms against a fluorogenic peptide substrate and gelatin, a natural substrate of the enzyme (14) . Furthermore, no evidence of cooperative interaction between the two active sites in terms of substrate hydrolysis and TIMP inhibition was observed, as determined by the enzyme kinetic studies with the peptide substrate. However, we have found a significant difference in the catalytic efficiency of pro-MMP-9 M and pro-MMP-9 D activation by stromelysin 1 with pro-MMP-9 D being activated with a lower efficiency (10-fold), as indicated by k cat /K m values for the activation reaction. The K m values are in the nanomolar range for both pro-MMP-9 forms, consistent with the fact that stromelysin 1 is readily saturated by pro-MMP-9 (44, 45) . The K m values in the nanomolar range have also been observed for a number of proteolytic enzymes of the blood coagulation cascade with their substrates (47) . Since catalysis is very slow, K m equals K s . This indicates that the affinity (K s ) of stromelysin 1 for proMMP-9 is high. For the same reason, k cat ϭ k 2 . The microscopic rate constant k 2 is that for the peptide hydrolysis (hydrolytic) step, beyond the Michaelis-Menten complex. It is of interest that k cat values for turnover of the two forms of pro-MMP-9 are exceedingly small (in the range of 10 Ϫ3 to 10 Ϫ4 s Ϫ1 ; Table I ). A low K m is consistent with a low value for k cat , since the ratio k cat /K m has a limit set by the rate of diffusion. However, the resultant k cat /K m values are in the respectable range of 10 4 to 10
. These values further suggest that stromelysin 1 is an efficient physiological activator of pro-MMP-9 (48).
The low k cat values for activation of the two pro-MMP-9 forms by stromelysin 1 are worthy of comment. Highly catalytically competent enzymes, which often operate at the diffusion limit, may have k cat values in the range of 10 3 s Ϫ1 . Clearly, stromelysin 1 does not merit this distinction. This raises the question: why is the k cat value for the activation of pro-MMP-9 so low? The crystal structure of the catalytic domain of stromelysin 1 indicates that the active site is an extended cleft (43, 49, 50) . Proteases generally prefer unstructured peptides as substrates. This appears to be the case for stromelysin 1, based on the topology of its active site. The high affinity of stromelysin 1 for pro-MMP-9 indicates that the complex between the two enzymes forms readily, even in the nanomolar range for the pro-MMP-9 concentration. Despite this, turnover is slow (t 1/2 of 6.1 Ϯ 0.3 and 28 Ϯ 2 min computed from the k cat values for the monomeric and dimeric forms, respectively). Ogata et al. (45) first reported that the activation of pro-MMP-9 by stromelysin 1 is a sequential process involving two cleavage sites, first in the Glu 59 -Met 60 bond followed by the cleavage of the Arg 106 -Phe 107 peptide bond. The first cleavage generates an inactive 85-kDa intermediate form within seconds (44) , whereas the second cleavage site generates the fully active 82-kDa MMP-9 species (29, 45) . Fig. 5 shows a view of the energy-minimized computational model that we have generated for the catalytic domain of pro-MMP-9 and its requisite prodomain. As seen in this image, the Glu 59 -Met 60 bond is fully exposed near the surface of the protein, and hence would be accessible to stromelysin 1. Such a position would readily fit in the active site of stromelysin 1, and its hydrolysis is obviously rapid as discerned from the turnover in the range of several seconds. The fact that this cleavage occurs so readily facilitates measurement of the hydrolysis rate of the second cleavage, which results in zymogen activation. In essence, the product of the first cleavage, which is inactive, serves as the substrate for the activation event. Our model predicts that the Arg 106 -Phe 107 peptide bond is less accessible than the Glu 59 -Met 60 bond (Fig. 5) . The kinetics of pro-MMP-9 activation by stromelysin 1, measured in this study, are for the slow cleavage step and follow an uncomplicated standard profile for a single saturation event. For the second cleavage to take place, a required relaxation of structure will have to occur. This would entail dissociation of Cys 99 from coordination with the active site zinc ion (Fig. 5) . It is necessary that after the formation of the pro-MMP-9/stromelysin 1 complex, pro-MMP-9 relaxes its secondary structure around the activation site, prior to its fitting into the active site of stromelysin 1 and hydrolysis of the peptide bond. This relaxation of structure should be the slow step in the catalytic turnover of pro-MMP-9.
The calculated t 1/2 for pro-MMP-9 turnover falls within the range of the length of time needed for larger scale motions of proteins, such as helix-coil transitions for example (51) , which is consistent with our proposal for this local unfolding of the prodomain prior to its excision. It is also interesting to note that the pro-MMP-9 D is substantially more stable than the monomer form, based on the k cat values that we have measured. This is explained intuitively by the observation that protein-protein interactions, in this case by dimerization, stabilize the protein making it more difficult to unfold. Thus, a possible, but yet unproven, explanation to the lower rate of dimer activation may be a reduced ability of the dimer to undergo the necessary relaxation of structure to permit the catalytic hydrolysis of the prodomain by stromelysin 1. The significance of the slower rate of activation of the pro-MMP-9 dimer by stromelysin 1 for MMP-9-dependent proteolysis is unclear. However, it is tempting to speculate that the existence of the slow activating dimer may provide an additional level of control during ECM degradation by MMP-9 species. Furthermore, fluctuations in the relative amounts of latent monomer and dimer secreted into the extracellular milieu may also play a role in the control of MMP-9-dependent proteolysis. The biochemical and cellular processes regulating dimerization of pro-MMP-9 remain to be determined.
